Inside the study for a remedy to fight Congo's deadliest Ebola outbreak
The drug is targeted at Bundibugyo virus, which is responsible for the fast-moving outbreak and is without an approved vaccine or treatment. The trial began in July and is one of several studies launched to find some protection and another way of at least slowing the outbreak.
A trial is underway in the Democratic Republic of Congo for a drug that could prevent Ebola infection. The drug, obeldesivir, is targeted at the Bundibugyo virus, which is responsible for the current outbreak and has no approved vaccine or treatment. According to Medical Xpress, over 250 participants have been enrolled in the trial, which began in July.
The outbreak, declared in mid-May, has spread to seven provinces and has recorded at least 8,300 confirmed cases, including 4,000 deaths, as reported by Medical Xpress. The trial is one of several studies launched to find protection and slow the outbreak.
France has pledged to increase its support for efforts to control the outbreak, as stated by Foreign Minister Jean-Noël Barrot during a visit to the affected region, according to RFI English.
Brief written by urgent.news from PBS NewsHour Health, PBS NewsHour, RFI English, Medical Xpress, Winnipeg Free Press — 5 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
